Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More
Roche gets FDA nod for cobas EZH2 Mutation Test as companion diagnostic for follicular lymphoma patients
Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK (tazemetostat), ... Read More
Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma
Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular ... Read More